Toll Free: 1-888-928-9744

Liver Fibrosis - Pipeline Review, H1 2016

Published: Mar 30, 2016 | Pages: 193 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liver Fibrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H1 2016', provides an overview of the Liver Fibrosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
- The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Liver Fibrosis Overview 9 Therapeutics Development 10 Pipeline Products for Liver Fibrosis - Overview 10 Pipeline Products for Liver Fibrosis - Comparative Analysis 11 Liver Fibrosis - Therapeutics under Development by Companies 12 Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes 15 Liver Fibrosis - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Liver Fibrosis - Products under Development by Companies 18 Liver Fibrosis - Products under Investigation by Universities/Institutes 21 Liver Fibrosis - Companies Involved in Therapeutics Development 22 Advinus Therapeutics Ltd. 22 AiCuris GmbH & Co. KG 23 Akarna Therapeutics Ltd. 24 Angion Biomedica Corp. 25 Asubio Pharma Co., Ltd. 26 Bioneer Corporation 27 BiOrion Technologies B.V. 28 Bird Rock Bio, Inc. 29 Bristol-Myers Squibb Company 30 Celgene Corporation 31 Dicerna Pharmaceuticals, Inc. 32 Digna Biotech, S.L. 33 Dr. Falk Pharma GmbH 34 Dynavax Technologies Corporation 35 Evotec AG 36 FibroGen, Inc. 37 Galectin Therapeutics, Inc. 38 Genfit SA 39 Gilead Sciences, Inc. 40 GNI Group Ltd. 41 HEC Pharm Co., Ltd. 42 Immuron Limited 43 Intercept Pharmaceuticals, Inc. 44 INVENT Pharmaceuticals, Inc. 45 Isarna Therapeutics GmbH 46 KineMed, Inc. 47 LG Life Science LTD. 48 Nitto Denko Corporation 49 Pfizer Inc. 50 Pharmaxis Limited 51 Promedior, Inc. 52 Promethera Biosciences S.A. 53 ProMetic Life Sciences Inc. 54 RXi Pharmaceuticals Corporation 55 SciFluor Life Sciences, LLC 56 TCM Biotech International Corp 57 Vascular Biogenics Ltd. 58 Virobay Inc. 59 XTuit Pharmaceuticals, Inc. 60 Liver Fibrosis - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 66 Assessment by Route of Administration 69 Assessment by Molecule Type 71 Drug Profiles 73 AIC-649 - Drug Profile 73 ANG-3070 - Drug Profile 74 ANG-3281 - Drug Profile 75 ANG-4011 - Drug Profile 76 Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 77 Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 78 Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 79 ASB-14780 - Drug Profile 80 BMS-986171 - Drug Profile 81 BOT-162 - Drug Profile 82 CC-539 - Drug Profile 83 CIGB-500 - Drug Profile 84 CPI-43132 - Drug Profile 85 CT-140 - Drug Profile 86 DB-036 - Drug Profile 87 Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 88 Drugs for Tissue Fibrosis - Drug Profile 89 DV-1079 - Drug Profile 90 F-351 - Drug Profile 92 FG-3019 - Drug Profile 94 GM-CT-01 - Drug Profile 96 GRMD-02 - Drug Profile 99 HEC-00000585 - Drug Profile 102 HepaStem - Drug Profile 103 IMM-124E - Drug Profile 105 INT-767 - Drug Profile 107 INV-340 - Drug Profile 109 ISTH-0047 - Drug Profile 110 KW-0 - Drug Profile 112 LC-280126 - Drug Profile 113 melittin - Drug Profile 115 MOR-8457 - Drug Profile 116 ND-L02s0201 - Drug Profile 117 norursodeoxycholic acid - Drug Profile 119 noscapine - Drug Profile 121 PBI-4050 - Drug Profile 122 PRM-151 - Drug Profile 124 PXS-5033A - Drug Profile 126 Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 127 RXI-209 - Drug Profile 128 RYI-018 - Drug Profile 129 selonsertib - Drug Profile 130 selonsertib + simtuzumab - Drug Profile 131 Small Molecule for Liver Fibrosis - Drug Profile 132 Small Molecule for Liver Fibrosis - Drug Profile 133 Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile 134 Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 135 Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile 136 Small Molecules for Fibrosis - Drug Profile 137 Small Molecules for Hepatic Fibrosis - Drug Profile 138 Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 139 Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 140 TCM-808FB - Drug Profile 141 TGFTX-4 - Drug Profile 142 VB-201 - Drug Profile 143 VBY-376 - Drug Profile 145 VBY-825 - Drug Profile 146 Liver Fibrosis - Recent Pipeline Updates 147 Liver Fibrosis - Dormant Projects 177 Liver Fibrosis - Discontinued Products 180 Liver Fibrosis - Product Development Milestones 181 Featured News & Press Releases 181 Appendix 188 Methodology 188 Coverage 188 Secondary Research 188 Primary Research 188 Expert Panel Validation 188 Contact Us 188 Disclaimer 189
List of Tables
Number of Products under Development for Liver Fibrosis, H1 2016 14 Number of Products under Development for Liver Fibrosis - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Development by Companies, H1 2016 (Contd..1) 17 Number of Products under Development by Companies, H1 2016 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2016 25 Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd., H1 2016 26 Liver Fibrosis - Pipeline by AiCuris GmbH & Co. KG, H1 2016 27 Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H1 2016 28 Liver Fibrosis - Pipeline by Angion Biomedica Corp., H1 2016 29 Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H1 2016 30 Liver Fibrosis - Pipeline by Bioneer Corporation, H1 2016 31 Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016 32 Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H1 2016 33 Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2016 34 Liver Fibrosis - Pipeline by Celgene Corporation, H1 2016 35 Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 36 Liver Fibrosis - Pipeline by Digna Biotech, S.L., H1 2016 37 Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 38 Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H1 2016 39 Liver Fibrosis - Pipeline by Evotec AG, H1 2016 40 Liver Fibrosis - Pipeline by FibroGen, Inc., H1 2016 41 Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016 42 Liver Fibrosis - Pipeline by Genfit SA, H1 2016 43 Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H1 2016 44 Liver Fibrosis - Pipeline by GNI Group Ltd., H1 2016 45 Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H1 2016 46 Liver Fibrosis - Pipeline by Immuron Limited, H1 2016 47 Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 48 Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 49 Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2016 50 Liver Fibrosis - Pipeline by KineMed, Inc., H1 2016 51 Liver Fibrosis - Pipeline by LG Life Science LTD., H1 2016 52 Liver Fibrosis - Pipeline by Nitto Denko Corporation, H1 2016 53 Liver Fibrosis - Pipeline by Pfizer Inc., H1 2016 54 Liver Fibrosis - Pipeline by Pharmaxis Limited, H1 2016 55 Liver Fibrosis - Pipeline by Promedior, Inc., H1 2016 56 Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H1 2016 57 Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016 58 Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 59 Liver Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016 60 Liver Fibrosis - Pipeline by TCM Biotech International Corp, H1 2016 61 Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H1 2016 62 Liver Fibrosis - Pipeline by Virobay Inc., H1 2016 63 Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H1 2016 64 Assessment by Monotherapy Products, H1 2016 65 Assessment by Combination Products, H1 2016 66 Number of Products by Stage and Target, H1 2016 68 Number of Products by Stage and Mechanism of Action, H1 2016 71 Number of Products by Stage and Route of Administration, H1 2016 74 Number of Products by Stage and Molecule Type, H1 2016 76 Liver Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016 151 Liver Fibrosis - Dormant Projects, H1 2016 181 Liver Fibrosis - Dormant Projects (Contd..1), H1 2016 182 Liver Fibrosis - Dormant Projects (Contd..2), H1 2016 183 Liver Fibrosis - Discontinued Products, H1 2016 184


List of Figures
Number of Products under Development for Liver Fibrosis, H1 2016 14 Number of Products under Development for Liver Fibrosis - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Investigation by Universities/Institutes, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Products, H1 2016 21 Assessment by Monotherapy Products, H1 2016 65 Number of Products by Top 10 Targets, H1 2016 67 Number of Products by Stage and Top 10 Targets, H1 2016 67 Number of Products by Top 10 Mechanism of Actions, H1 2016 70 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 70 Number of Products by Routes of Administration, H1 2016 73 Number of Products by Stage and Routes of Administration, H1 2016 73 Number of Products by Top 10 Molecule Types, H1 2016 75 Number of Products by Stage and Top 10 Molecule Types, H1 2016 75

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify